Uterine leiomyomas are a common and significant health issue for women, with an estimated cumulative incidence by age 50 years of more than 80% in black women and nearly 70% in white women.^[@R1]^ Up to 50% of women with uterine leiomyomas are symptomatic,^[@R2]^ with clinical symptoms that can include abnormal uterine bleeding (AUB), anemia, abdominal pressure and pain, increased urinary frequency, and infertility.^[@R1]--[@R5]^ Uterine leiomyoma symptoms interfere with daily physical and social activities, and negatively affect women\'s well-being and health-related quality of life (QOL).^[@R6]--[@R8]^

Uterine leiomyomas are the leading indication for hysterectomy in the United States,^[@R9],[@R10]^ but studies have shown that most women with uterine leiomyomas would prefer minimally invasive or noninvasive treatment options.^[@R6],[@R11]^ There are no pharmacologic treatments indicated outside of preoperative use for women with symptomatic uterine leiomyomas.

Ulipristal acetate is an orally administered selective progesterone receptor modulator^[@R12]--[@R15]^ that acts on the progesterone receptors of the endometrium, leiomyoma tissue, and pituitary gland to reduce bleeding and uterine leiomyoma size.^[@R16]--[@R21]^ Ulipristal has demonstrated efficacy compared with placebo in clinical trials.^[@R17],[@R22],[@R23]^ Two pivotal phase 3 studies---VENUS I and VENUS II---confirmed the efficacy of ulipristal for the treatment of women with symptomatic uterine leiomyomas: in both studies, rate of and time to amenorrhea was superior for ulipristal 5 mg or 10 mg compared with placebo (*P*\<.001).^[@R24],[@R25]^

The objective of this analysis was to provide a more robust and in-depth investigation of the effects of ulipristal on health-related QOL and symptom severity for patients in the VENUS I and VENUS II studies.
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==========================
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METHODS {#s2}
=======

VENUS I (UL1309; ClinicalTrials.gov: NCT02147197)^[@R24]^ and VENUS II (UL1208; [ClinicalTrials.gov](http://ClinicalTrials.gov): NCT02147158)^[@R25]^ were phase 3, randomized, placebo-controlled, multicenter studies designed to evaluate the efficacy and safety of ulipristal for the treatment of AUB associated with uterine leiomyomas. Each institution obtained approval from a central or local Institutional Review Board (IRB) before study initiation, and written informed consent was acquired from all study participants. The institutions involved were approved by one of the following IRBs: Shulman Associates IRB, Western IRB, Medical University of South Carolina IRB, Hamilton Integrated Research Ethics Board, Ottawa Health Science Network Research Ethics Board, Chesapeake IRB, and Virtua General IRB. VENUS I assessed a single 12-week treatment course of ulipristal, whereas VENUS II evaluated intermittent therapy with two 12-week treatment courses separated by a drug-free interval of two menses. Both studies included a 12-week, drug-free, follow-up period.

In VENUS I, patients were randomized in a 1:1:1 ratio to receive either ulipristal 5 mg, ulipristal 10 mg, or placebo orally, once daily (Fig. [1](#F1){ref-type="fig"}A).^[@R24]^ In VENUS II, patients were randomized to one of six treatment arms in a 1:1:2:1:2:1 ratio, with course 1, course 2 dosing of placebo, ulipristal 5 mg; placebo, ulipristal 10 mg; ulipristal 5 mg, 5 mg; ulipristal 5 mg, placebo; ulipristal 10 mg, 10 mg; ulipristal 10 mg, placebo (Fig. [1](#F1){ref-type="fig"}B).^[@R25]^ The treatment arms of the individual studies were pooled (Fig. [1](#F1){ref-type="fig"}C).

![Treatment randomization in VENUS I (**A**) and VENUS II (**B**) and subsequent pooling of treatment groups (**C**). UPA, ulipristal acetate.\
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Patient inclusion and exclusion criteria (the same for VENUS I and II) have been described elsewhere.^[@R24],[@R25]^ In brief, key inclusion criteria included premenopausal women aged 18--50 years who had experienced cyclic (between 22 and 35 menstrual cycle length days) AUB, had menstrual blood loss of 80 mL or greater (measured using alkaline hematin), and had at least one discrete leiomyoma observable by transvaginal ultrasound examination. Key exclusion criteria included a history of uterine surgery that would interfere with the study endpoints, known coagulation disorder, and a history of or current, uterine, cervix, ovarian, or breast cancers. Patients with alanine transaminase, aspartate transaminase, alkaline phosphatase, or total bilirubin two or more times the upper limit of normal at screening were excluded.

The Uterine Fibroid Symptom Health-Related Quality of Life questionnaire 1-month recall version is a 37-item questionnaire developed and validated specifically to evaluate the symptoms of uterine leiomyomas and their effect on health-related QOL for women with uterine leiomyomas (Coyne KS, Harrington A, Currie BM, Chen J, Gillard P, Spies JB. Psychometric validation of the 1-month recall uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Poster PRM87 presented at ISPOR 23rd annual international meeting, May 19--23, 2018, Baltimore, MD.).^[@R26]--[@R29]^ The Uterine Fibroid Symptom and Health-Related Quality of Life scales were transformed into scores that range from 0--100, with higher scores indicating better health-related QOL; for the Symptom Severity scale, higher scores signified greater symptom severity.

Mean change from baseline at the end of treatment course 1 on the Revised Activities subscale score of the Uterine Fibroid Symptom Health-Related Quality of Life questionnaire was a prespecified secondary endpoint in VENUS I and II. Mean change from baseline at end of treatment (VENUS I) or end of treatment courses 1 and 2 (VENUS II) on the Uterine Fibroid Symptom Health-Related Quality of Life questionnaire Symptom Severity, Health-Related QOL Total scale, and the other health-related QOL subscale scores were other efficacy measurements.

VENUS I and VENUS II were considered suitable for pooling based on similarities in study design, treatment, study population, and endpoints; the pooled analysis was a planned secondary analysis agreed to with the U.S. Food and Drug Administration in June 2016. Changes from baseline to end of treatment for each Uterine Fibroid Symptom Health-Related Quality of Life questionnaire scale score were analyzed using pooled data from VENUS I and VENUS II (treatment course 1 only). Changes from baseline to end of treatment courses 1 and 2 for each Uterine Fibroid Symptom Health-Related Quality of Life questionnaire scale score were analyzed using data from VENUS II for each treatment arm.

Responder thresholds were determined in a separate study using a triangulation approach considering distribution-based (eg, effect size), clinical relevancy-based (eg, absence of bleeding and controlled bleeding), and anchor-based analyses (eg, patient perception of change) (Coyne KS, Harrington A, Currie BM, Mo Y, Gillard P, Spies JB. A meaningful response on the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL) \[abstract\]. Fertil Steril 2018;110(suppl):e135--6.). A responder threshold of at least a 20-point improvement from baseline was determined to be a meaningful improvement on the Symptom Severity and Health-Related QOL Total scales, and at least a 30-point improvement on the Revised Activities subscale (Coyne et al, Fertil Steril 2018;110(suppl):e135--6.).

The intent-to-treat population, which included all randomized patients, was the primary population for all analyses. Observed cases were also used, including assessments collected at each scheduled visit; this visit type was used in by-visit analyses of the Uterine Fibroid Symptom Health-Related Quality of Life questionnaire data. Patient disposition, demographics, and other baseline characteristics for the pooled data set were analyzed using descriptive statistics. In pooled analyses, the *P* value of the least-square mean difference between ulipristal treatment and placebo was from an analysis of covariance model with treatment as the main effect, and study, baseline value, and pooled center as covariates. Least-square means are adjusted for the terms in the model (study, baseline value, and pooled center) and are less sensitive to missing data. In VENUS II, the difference between change from baseline to end of treatment course 1 and change from baseline to end of treatment course 2 was analyzed using the paired *t*-test in each treatment arm. All statistical tests were two-sided hypothesis tests performed at the 2.5% level of significance, that is, an a priori *P* value of .05 was set unless otherwise mentioned. All *P* values were considered nominal as a measure of strength of association between the endpoint and the treatment effect.

Responder analyses for the Symptom Severity and Health-Related QOL Total scales, and the Revised Activities subscale, were performed post hoc in the pooled VENUS I and II population (treatment course 1 only). The *P* value from the Cochran-Mantel-Haenszel test compared odds ratios (ORs) for responder status between different treatment arms, controlling for pooled center.Authors\' Data Sharing StatementWill individual participant data be available (including data dictionaries)? *Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2--4 trials completed after 2008 that are registered to* [*ClinicalTrials.gov*](http://ClinicalTrials.gov) *or EudraCT, have received regulatory approval in the United States or the European Union in a given indication, and the primary manuscript from the trial has been published.*What data in particular will be shared? *See above.*What other documents will be available? *See above.*When will data be available (start and end dates)? *See above.*By what access criteria will data be shared (including with whom, for what types of analyses, and by what mechanism)? *To request access to the data, the researcher must sign a data-use agreement, and any shared data are to be used for noncommercial purposes. More information can be found at* [*http://www.allerganclinicaltrials.com/*](http://www.allerganclinicaltrials.com/)*.*

RESULTS {#s3}
=======

In total, 589 patients were included in both studies (placebo, n=169; ulipristal 5 mg, n=215; ulipristal 10 mg, n=205). Demographic and baseline characteristics were similar across treatment arms (Table [1](#T1){ref-type="table"}). In the total population, mean (SD) age was 41.1 (5.5) years, 67.4% of women (n=397) were black or African American, mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 32.1 (7.9), and mean (SD) menstrual blood loss was 212.1 (155.1) mL. At baseline, mean (SD) Uterine Fibroid Symptom Health-Related Quality of Life questionnaire Revised Activities subscale scores in the placebo, ulipristal 5-mg, and 10-mg groups were 30.7 (25.3), 28.1 (23.8), and 32.0 (26.2), respectively. At baseline, mean (SD) health-related QOL Total scores in the placebo, ulipristal 5-mg, and 10-mg groups were 33.2 (22.0), 32.3 (20.8), and 35.5 (22.6), respectively.

###### 

Baseline Demographic and Clinical Characteristics: Pooled VENUS I and VENUS II

![](ong-133-869-g002)

For the pooled analysis, at the end of treatment, significantly greater improvements in Symptom Severity from baseline were observed for both ulipristal doses compared with placebo (Table [2](#T2){ref-type="table"}). The least-square mean differences on the Symptom Severity scale score in the ulipristal 5-mg and 10-mg groups compared with placebo (97.5% CI) were −22.8 (−28.0 to −17.6) and −30.2 (−35.5 to −24.9) (both *P*\<.001).

###### 

Secondary and Other Efficacy Endpoints: Baseline, End of Treatment, and Least Square Mean Difference in Change From Baseline in Uterine Fibroid Symptom Health-Related Quality of Life Questionnaire Scale Scores (Pooled VENUS I and VENUS II)

![](ong-133-869-g003)

Significantly greater improvements from baseline in Uterine Fibroid Symptom Health-Related Quality of Life questionnaire health-related QOL Total score were observed for both ulipristal doses compared with placebo at end of treatment (Table [2](#T2){ref-type="table"}): least-square mean differences in the ulipristal 5-mg and 10-mg groups compared with placebo (97.5% CI) were 29.5 (23.8--35.3) and 37.7 (31.8--43.6) (both *P*\<.001). At end of treatment, significantly greater improvements from baseline in all health-related QOL subscale scores were observed for both ulipristal doses compared with placebo (Table [2](#T2){ref-type="table"}). For example, the least-square mean differences in the Activities subscale score in the ulipristal 5-mg and 10-mg groups compared with placebo (97.5% CI) were 32.9 (26.7--39.1) and 41.0 (34.6--47.3) (both *P*\<.001).

Significantly greater improvements from baseline in physical and social activities, as measured by the Revised Activities subscale, were observed for both ulipristal doses compared with placebo at end of treatment (Table [2](#T2){ref-type="table"}). The least-square mean differences on the Uterine Fibroid Symptom Health-Related Quality of Life questionnaire Revised Activities subscale score in the ulipristal 5-mg and 10-mg groups compared with placebo (97.5% CI) were 34.0 (27.6--40.4) and 42.2 (35.6--48.7) (both *P*\<.001).

An improvement for Symptom Severity of 20 or more points was achieved among 35.2% of patients (n=51) in the placebo group, 71.4% (n=140) in the ulipristal 5-mg group (OR 4.7; 97.5% CI 2.7--8.2), and 79.6% (n=140) in the ulipristal 10-mg group (OR 7.8; 97.5% CI 4.3--14.2) (Table [3](#T3){ref-type="table"}). A Health-Related QOL Total score improvement of 20 or more points was achieved by 35.9% of patients (n=51) in the placebo group, 77.4% (n=151) in the ulipristal 5-mg group (OR 5.8; 97.5% CI 3.3--10.2), and 86.8% (n=151) in the ulipristal 10-mg group (OR 12.5; 97.5% CI 6.5--24.2) (Table [3](#T3){ref-type="table"}). An improvement of 30 or more points for the Revised Activities subscale was achieved by 34.9% of patients (n=51) in the placebo group, 73.5% (n=144) in the ulipristal 5-mg group (OR 5.0; 97.5% CI 2.9--8.6), and 80.6% (n=141) in the ulipristal 10-mg group (OR 7.9; 97.5% CI 4.3--14.6) (Table [3](#T3){ref-type="table"} and Fig. [2](#F2){ref-type="fig"}). A lack of improvement in the Revised Activities subscale was reported by approximately 25%, 8%, and 5% of patients in the placebo, ulipristal 5-mg, and ulipristal 10-mg groups, respectively (Fig. [2](#F2){ref-type="fig"}).

###### 

Post Hoc Analysis: Meaningful Improvements in the Uterine Fibroid Symptom Health-Related Quality of Life Questionnaire Symptom Severity (20 or More Points), Health-Related Quality of Life Total (20 or More Points), and Revised Activities (30 or More Points) Scale Scores (Pooled VENUS I and VENUS II)

![](ong-133-869-g004)

![Cumulative distribution function for change from baseline in Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFS-QOL) Revised Activities subscale score at end of treatment (end of treatment in VENUS I and end of treatment course 1 in VENUS II): pooled VENUS I and VENUS II. The *vertical line* denotes the responder threshold. A responder is defined as a patient who achieved 30 or more points of improvement in change from baseline on the Revised Activities subscale score of the UFS-QOL at end of treatment. UPA, ulipristal acetate.\
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For VENUS II, at the end of both treatment courses, both ulipristal doses showed greater improvement compared with placebo in change from baseline on the Symptom Severity scale score (*P*\<.001), Uterine Fibroid Symptom Health-Related Quality of Life questionnaire Health-Related QOL Total score (*P*\<.001), and all other Uterine Fibroid Symptom Health-Related Quality of Life questionnaire subscale scores (treatment course 1: *P*\<.001; treatment course 2: *P*\<.01). For example, a significant improvement in the Uterine Fibroid Symptom Health-Related Quality of Life questionnaire Revised Activities subscale score was observed for both ulipristal doses compared with placebo (both *P*\<.001) at the end of both treatment courses (Fig. [3](#F3){ref-type="fig"}). Significant improvements in Uterine Fibroid Symptom Health-Related Quality of Life questionnaire scale scores were observed on switching from placebo in treatment course 1 to ulipristal in treatment course 2 (Fig. [3](#F3){ref-type="fig"}). In contrast, women receiving ulipristal in treatment course 1 who switched to placebo in treatment course 2 had a significant loss of health-related QOL on the Uterine Fibroid Symptom Health-Related Quality of Life questionnaire scales, although these values did not return to baseline (Fig. [3](#F3){ref-type="fig"}).

![Baseline and end of treatment courses 1 and 2 Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire scale scores in the treatment arms of VENUS II. Symptom Severity (**A**), Activities (original) (**B**), Revised Activities (**C**), Concern (**D**), Control (**E**), Energy/Mood (**F**), Self-Consciousness (**G**), Sexual Function (**H**), and Health-Related Quality of Life Total (**I**). *P* values are from the paired *t*-test comparing the mean difference between baseline and end of treatment course 1 and baseline and end of treatment course 2. *P*\<.001 in the following treatment arms: placebo:UPA 5 mg, placebo:UPA 10 mg, UPA 5 mg:placebo, and UPA 10 mg:placebo, for all scales except control, UPA 10 mg:placebo (*P*=.001) and sexual function, UPA 5 mg:placebo (*P*=.004). *P*≥.05 in the following treatment arms: UPA 5 mg:UPA 5 mg and UPA 10 mg:UPA 10 mg, for all scales except Activities (original), *P*=.046, Revised Activities, *P*=.041, and Control, *P*=.003, in the UPA 10 mg:UPA 10 mg arm. Placebo:UPA 5 mg, n=39--40; placebo:UPA 10 mg, n=36--38; UPA 5 mg:placebo, n=38--40; UPA 10 mg:placebo, n=27; UPA 5 mg:UPA 5 mg, n=77; UPA 10 mg:UPA 10 mg, n=73--74. N indicates patients with analysis values at both baseline and postbaseline during the specified time period. Revised Activities subscale score is not included in the Health-Related Quality of Life Total score. UPA, ulipristal acetate.\
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DISCUSSION {#s4}
==========

Women\'s health-related QOL and well-being, including daily physical and social activities, are known to be negatively affected by the symptoms of uterine leiomyomas.^[@R6]--[@R8]^ Women with uterine leiomyomas experience significantly lower health-related QOL than healthy control individuals, as measured by the Short-Form 36 health survey.^[@R26],[@R29]^ Women with severe uterine leiomyoma symptoms had significantly worse health-related QOL measured by Uterine Fibroid Symptom Health-Related Quality of Life questionnaire scores than women with mild or moderate symptoms. Uterine Fibroid Symptom Health-Related Quality of Life questionnaire subscale scores also worsened as the number of symptoms increased.^[@R30]^

Hysterectomy continues to be the most common surgical treatment for uterine leiomyomas, with rates of 21--53% in the United States.^[@R31]^ With no pharmacologic treatments indicated other than for preoperative therapy for women with symptomatic uterine leiomyomas, many are used off-label, including gonadotropin-releasing hormone agonists and tranexamic acid,^[@R32]--[@R34]^ nonsteroidal antiinflammatories, levonorgestrel intrauterine devices, and oral and nonoral combination contraceptives.^[@R33]--[@R36]^ Thus, there is a significant unmet need for oral therapy for the treatment of uterine leiomyomas that is effective and safe, and can be used both presurgery and postsurgery.

Ulipristal is the first oral therapy to demonstrate efficacy and safety in the treatment of uterine leiomyomas in multiple phase 3 studies: PEARL I--IV^[@R17],[@R18],[@R22],[@R23],[@R37]^ and VENUS I and II.^[@R24],[@R25]^ This analysis shows that, in addition to its demonstrated efficacy and safety, ulipristal is effective at improving the health-related QOL and symptom severity of women with symptomatic uterine leiomyomas, including their ability to engage in physical and social activities.

The population in the pooled VENUS I and VENUS II studies is representative of women with uterine leiomyomas in the U.S. general population, and reflects the higher incidence of uterine leiomyomas in black or African American women, which is two to three times higher than in white women after accounting for age and other risk factors.^[@R38],[@R39]^ Treatment with ulipristal 5 mg and 10 mg improved patients\' symptoms and health-related QOL in this population. Although a small proportion of patients experienced no change or some worsening in these outcomes, the majority of women reported clear improvements, for example, more than 70% of patients in the ulipristal treatment arms achieved a meaningful improvement of 30 or more points on the Revised Activities subscale (a 0--100 scale).

The VENUS II analysis showed that the beneficial effects of ulipristal were not completely maintained when women switched to placebo. In contrast, women who started on placebo achieved improvement in Uterine Fibroid Symptom Health-Related Quality of Life questionnaire scores after one treatment course of ulipristal and, for women who received ulipristal in both treatment courses, the benefits of ulipristal were maintained from one treatment course to the next.

The strengths of this health-related QOL analysis include the use of a validated instrument^[@R26],[@R27],[@R29]^ and the advantages of pooling studies with very similar designs. Limitations include that the pooled analyses only assessed up to two treatment courses; therefore, the effect of treatment over an extended period of time was not investigated.

In conclusion, ulipristal treatment was associated with significant improvements in health-related QOL and symptom severity compared with placebo for women with symptomatic uterine leiomyomas. Improvements in health-related QOL, taken together with the significant improvements in amenorrhea, suggest that ulipristal is a promising, noninvasive treatment option for women suffering from symptomatic uterine leiomyomas.
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